PF-06647263
Product Specifications
UNSPSC Description
PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody, ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts[1][2].
Target Antigen
Antibiotic; Antibody-Drug Conjugates (ADCs); Apoptosis; DNA Alkylator/Crosslinker
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related;Anti-infection;Apoptosis;Cell Cycle/DNA Damage
Applications
COVID-19-immunoregulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pf-06647263.html
Smiles
[PF-06647263]
References & Citations
[1]Garrido-Laguna I, et al. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019 Oct 1;145(7):1798-1808. |[2]Damelin M, et al. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. Clin Cancer Res. 2015 Sep 15;21(18):4165-73.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-111965/PF-06647263-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-111965/
Clinical Information
Phase 1
CAS Number
1822383-65-2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7179041 Inquire
Rabbit anti-Escherichia coli O103:H2 (strain 12009/EHEC) RUTF Polyclonal Antibody
Ask
View Details